Area of research
Oncology · Dermatology
Research interest
Research interests include Cutaneous Melanoma Detection and Management, Cancer Immunotherapy and Biomarkers, Cutaneous lymphoproliferative disorders research, and Allergic Rhinitis and Sensitization.
MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.
Discordance, accuracy and reproducibility study of pathologists' diagnosis of melanoma and melanocytic tumors.
Real-World Pattern-of-Care Analysis of Primary Cutaneous Lymphomas Radiation Therapy Among European Organisation for Research and Treatment of Cancer Members.
Re-resection of brain metastases - outcomes of an institutional cohort study and literature review.
Clinical characteristics and outcomes in leptomeningeal disease with or without brain metastasis: insights from an explorative data analysis of the Charité LMD registry.
How to treat primary cutaneous B cell lymphoma - Results from a monocentric cohort study on 98 patients.
Is Kaposi sarcoma a novel comorbidity of cutaneous lymphoma? A systematic review of the literature.
Treatment at the end of life in patients with advanced melanoma. A multicenter DeCOG study of 1067 patients from the prospective skin cancer registry ADOReg.
Cetuximab plus 5-fluorouracil in patients with advanced cutaneous squamous cell carcinoma: a retrospective cohort study.
Real-world management of patients with complete response under immune-checkpoint inhibition for advanced melanoma.
Table 3 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
Figure 3 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
Table 2 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
Supplementary Data 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
Figure 2 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients.
Figure 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
Table 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
Data from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
Supplementary Table S1 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Supplementary Table S11 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Supplementary Tables S6-S9 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Supplementary Figure S2 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Supplementary Table S3 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Supplementary Table S10 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Supplementary Figure S1 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Data from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Supplementary Figure S3 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma
Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma.
Supplementary Table S4 from Multimodal Approach Predicts Relapse upon Cessation of Immune Checkpoint Inhibitors in Advanced Melanoma